摘要
目的Gankyrin是近年发现的一种癌基因。研究表明,Gankyrin参与多种肿瘤的发生、发展过程。本研究探讨Gankyrin在乳腺浸润性导管癌和癌前病变组织中的表达及临床意义。方法收集2012-01-01-2018-06-30临沂市妇女儿童医院病理科存档的27例正常乳腺导管、48例普通型导管增生、62例非典型导管增生、47例导管原位癌和89例浸润性导管癌(invasive ductalc arcinomas,IDC)标本,免疫组化检测Gankyrin在上述组织中的表达,并分析Gankyrin表达与乳腺浸润性导管癌临床病理学特征的关系。结果Gankyrin在正常乳腺导管、普通型导管增生、非典型导管增生、导管原位癌和浸润性导管癌组织的阳性表达率逐渐升高,分别为7.4%(2/27)、12.5%(6/48)、41.9%(26/62)、61.7%(29/47)和80.9%(72/89),υ=4,χ^2=84.764,P<0.001.Gankyrin在IDC中的表达与临床分期(υ=1,χ^2=3.894,P=0.048)、脉管侵犯υ=1,χ^2=4.160,P=0.041)和转移(υ=1,χ^2=4.175,P=0.041)有关联。结论Gankyrin在乳腺癌和癌前病变组织中高表达。Gankyrin可能参与乳腺癌的发生、发展,有望成为乳腺癌早期诊断和防治的靶点。
OBJECTIVE It is reported that Gankyrin,newly found oncogene,participated in the carcinogenesis and development of various cancers.In this study,the Gankyrin expression and clinical significance in breast invasive ductal carcinomas(IDC)and precancerous lesions were invesrtigated.METHODS Immunohistochemistry was performed to detect the Gankyrin expression in 27 cases of normal ducts(ND),48 cases of usual ductal hyperplasia(UDH),62 cases of atypical ductal hyperplasia(ADH),47 cases of ductal carcinoma in situ(EXDIS),and 89 cases of IDC in Department of Pathology,the Women and Child Hospital of Linyi between January 1,2012 and June 30,2018.Meanwhile,the relationship between the Gankyrin expression and the clinicopathological features of patients with IDCs was analyzed.RESULTS The positive rates of Gankyrin expression in ND,UDH.ADH,EX2IS,and IDC were gradually increased,with the rates of 7.4%(2/27),12.5%(6/48),41.9%(26/62),61.7%(29/47),and 80.9%(72/89;υ=4,χ^2=84.764,P<0.001).The Gankyrin expression in IDCs was significantly corelated with clinical stage(υ=1,χ^2=3.894,P=0.048),vascular invision(υ=1,χ^2=4.160,P=0.041)and metastasis(υ=1,χ^2=4.175,P=0.041)of IDCs.CONCLUSION Gankyrin is overexpressed in breast carcinomas and precancerious lesions,suggesting Gankyrin may play an important role in the occurance and development of brease carcinomas and may be a potential target for the early diagnosis,prevention and treatment of breast carcinomas.
作者
刘荣美
王爱军
厉善波
梁静
李寅
LIU Rong-mei;WANG Ai-jun;LI Shan-bo;LIANG Jing;LI Yin(Women and Child Hospital of Linyi,Linyi 276000,P.R.China;Department of Clinical Medicine,Grade 2015,Shandong First Medical University,Taian 271000,P.R.China)
出处
《中华肿瘤防治杂志》
CAS
北大核心
2019年第14期1009-1013,共5页
Chinese Journal of Cancer Prevention and Treatment
作者简介
通讯作者:刘荣美,女,山东临沂人,副主任医师,主要从事妇科肿瘤病理诊断和基础研究工作。Tel:86-539-3216163,E-mail:liurongmei1970@163.com.
